Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects (Bezafibrate)

This study has been completed.
Groupe Hospitalier Pitie-Salpetriere
Information provided by (Responsible Party):
Mette Cathrine Oerngreen, Rigshospitalet, Denmark Identifier:
First received: September 23, 2009
Last updated: May 29, 2012
Last verified: May 2012
The investigators propose to evaluate the effect of bezafibrate on metabolism during exercise in 22 adult patients affected with carnitine palmitoyltransferase II (CPTII) or very-long chain acyl-CoA-dehydrogenase (VLCAD) deficiencies. This study will be an 9-month, randomized, double-blind, placebo-controlled crossover trial. The trial will be conducted in two centers: Institut de Myologie, Pitié-Salpêtrière Hospital in France, and Rigshospitalet, University of Copenhagen, in Denmark. The main criteria for assessing the potential effect of this drug will be the fat oxidation rate studied during a moderate workload on cycle ergometer, after infusion of stable isotopes (palmitate and glucose tracers).

Condition Intervention Phase
Carnitine Palmitoyltransferase II Deficiency
Very Long Chain Acyl Coa Dehydrogenase Deficiency
Drug: Bezafibrate
Other: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of the Effect of Bezafibrate on Muscle Metabolism During Exercise in Patients With CPTII and VLCAD Deficiency

Resource links provided by NLM:

Further study details as provided by Rigshospitalet, Denmark:

Primary Outcome Measures:
  • Fatty acid oxidation [ Time Frame: Two years ]

Secondary Outcome Measures:
  • Heart rate [ Time Frame: Two years ]

Enrollment: 12
Study Start Date: October 2009
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bezafibrate Drug: Bezafibrate
3 x 200 mg/ day
Placebo Comparator: Placebo Other: Placebo

  Show Detailed Description


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • CPT II or VLCAD deficiency

Exclusion Criteria:

  • Competing disorders
  • Liver or kidney disease
  • Allergy towards fibrates
  • Pregnancy and breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00983788

Neuromusculare Research Unit, Rigshospitalet
Copenhagen, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Groupe Hospitalier Pitie-Salpetriere
  More Information

References - Andresen BS, Olpin S, Poorthuis BJHM, Scholte HR, Vianey-Saban C, Wanders R et al. Am J Hum Genet 1999; 64: 478-494 - Bonnefont JP, Taroni F, Cavadini P, Cepanec C, Brivet M, Saudubray JM, Leroux JP, Demaugre F, (1996) Am J Hum Genet 58:971-978. - Demaugre F, Bonnefont JP, Colonna M, Cepanec C, Leroux JP, Saudubray JM. (1991) J Clin Invest 87:859-864. - DiMauro S, Melis-DiMauro PM. Science 1973;182: 929-931. - Djouadi F, Bonnefont JP, Thuillier L, Droin V, Khadom N, Munnich A, Bastin J. (2003a). Pediatr Res. 54:446-51 - Djouadi F, Bonnefont JP, Munnich A, Bastin J. (2003b). Mol Genet Metab.;78:112-8. - Djouadi F, Aubey F, Schlemmer D, Ruiter JPN, Wanders RJA, Strauss AW et al. Hum Mol Genet 2005; 18: 2495-2703 - Djouadi F, Aubey F, Schlemmer D, Ruiter JPN, Wanders RJA, Strauss AW et al. Hum Mol Genet 2005; 14:2695-2703. - Djouadi F, Aubey F, Schlemmer D, Gobin S, Laforet P, Wanders RJA, et al. J Inherit Metab Dis 2006; 29: 341-342. - Djouadi F, Bastin J, Laforêt P, Aubey F, Mogenet A, Romano S et al. ASHG 57th Annual meeting (2007). - Johansen K. Basal Sundhedsvidenskabelig statistik. Munksgaard, Denmark 2002 1st edition. - Lemberger T, Desvergne B, Wahli W (1996) Annu. Rev. Cell. Dev. Biol. 12:335-363. - Ørngreen MC, Ejstrup R, Vissing J. Neurology 2003; 61:559-561. - Ørngreen MC, Nørgaard MG, Sacchetti M, van Engelen BGM, Vissing J. Ann Neurol. 2004; 56:279-282. - Ørngreen MC, Dunø M, Ejstrup R, Christensen E, Schwartz M, Sacchetti M, Vissing J. Ann Neurol. 2005; 57:60-66. - Ørngreen MC, Schelhaas HJ, Jeppesen TD, Akman HO, Wevers RA, Andersen ST, Ter Laak HJ, van Diggelen OP, DiMauro S, Vissing J. INeurology, 2008;70(20):1876-82. - Roe CR, Sweetman L, Roe DS, David F, Brunengraber H. J Clin Invest 2002; 110: 259-269. - Vianey-Saban C, Divry P, Brivet M, Nada M, Zabot M-T, Mathieu M et al. Clin Chim Acta 1998; 269: 43-62.

Responsible Party: Mette Cathrine Oerngreen, MD, Rigshospitalet, Denmark Identifier: NCT00983788     History of Changes
Other Study ID Numbers: EudraCT: 2008-006704-27
Study First Received: September 23, 2009
Last Updated: May 29, 2012

Keywords provided by Rigshospitalet, Denmark:

Additional relevant MeSH terms:
Lipid Metabolism, Inborn Errors
Muscular Diseases
Mitochondrial Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipid Metabolism Disorders
Metabolic Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents processed this record on April 21, 2017